Because both of them are main proinflammatory cytokine released in so many viral conditions, ischemia and stroke, it is reasonable to hypothesize that interfering with inflammasome activation may prove to be beneficial in delaying development of several neurodegenerative diseases in which the IL-1 inflammatory response plays a pathogenic role. The gene discussed is IL1B; the disease is ischemia.